Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands

Deukeren, Désirée van; Heesterman, Berdine L.; Roelofs, Lianne; Kiemeney, Lambertus A.; Witjes, J. Alfred; Smilde, Tineke J.; Leenders, Geert J.L.H. van; Incrocci, Luca; Vanneste, Ben; Meijer, Richard P.; Siesling, Sabine; Bezooijen, Bart P. J. van; Aben, K.K.H.

doi:10.1016/j.ctarc.2022.100553

Cited by 14 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent studies have confirmed the predicted diagnostic delay [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ]. In a study conducted in Taiwan, Tsai et al [ 9 ] reported that admissions to breast outpatient clinics in hospitals decreased by 37% during the lockdown period, and breast cancer screening decreased by 22%.…”

Section: Discussionmentioning

confidence: 86%

Lymphadenopathies before and during the Pandemic COVID-19: Increasing Incidence of Metastases from Solid Tumors

Trasarti

Troiano

Biglietto

et al. 2022

JCM

View full text Add to dashboard Cite

Since December 2019, the world has experienced a pandemic caused by SARS-CoV-2, a virus which spread throughout the world. Anti-COVID19 measures were applied to limit the spread of the infection, affecting normal clinical practice. In 2020, studies on the possible impact of the pandemic considering the screening programs for early diagnosis of cancer were conducted, resulting in a prediction of delayed diagnosis of cancer. We performed a retrospective monocentric study on patients who present with the onset of lymphadenomegalies evaluated at our Hematological Department from February 2019 to October 2021 and undergoing excisional lymph-node biopsy. Three periods were considered: pre-pandemic, first pandemic period and second pandemic period (Group A, B and C). We included 258 patients who underwent a surgical biopsy and received a histological diagnosis. Hematological evaluation of outpatients sent by the general practitioner and surgical biopsies did not decrease among the three groups, despite limitations placed during this pandemic as well as new diagnoses of hematological malignancies. However, the diagnosis of metastatic cancer significantly increased from 2019 (7.8%) to 2021 (22.1%) (p = 0.042). Our data supports the hypothesis that the pandemic affected the national screening programs of early cancer detection.

show abstract

Section: Discussionmentioning

confidence: 86%

Lymphadenopathies before and during the Pandemic COVID-19: Increasing Incidence of Metastases from Solid Tumors

Trasarti

Troiano

Biglietto

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Nossiter et al reported that during the COVID-19 period the number of men diagnosed with PC decreased by one-third and more advanced disease was more frequently diagnosed, with the recommendation that urgent concerted action be taken to address the COVID-19-related deficits in PC services in order to mitigate their impact on long-term outcomes (15). Similarly, Deukeren et al observed a marked decline in PC diagnoses during the first COVID-19 wave, with changes in treatments that were temporary (16). In their view, although it was to be expected that the pandemic would significantly impact PC care, the magnitude of this impact is still unknown.…”

Section: Discussionmentioning

confidence: 99%

How has the COVID-19 pandemic influenced prostate cancer?—a tertiary single-centre analysis of oncological results, diagnosis and treatment times

Barreras¹,

Ojeda²,

Plaza³

et al. 2022

Transl Androl Urol

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) pandemic has affected care for diseases like cancer. The aim was to evaluate the impact of COVID-19 on waiting times for diagnosis and treatment of prostate cancer (PC), as well as the possible effect on the treatment results in PC patients undergoing radical prostatectomy. Methods:We compared the results of 497 patients who underwent biopsy prior to the COVID-19 pandemic (1 January-31 December 2019) with those of 290 patients biopsied during the COVID-19 pandemic (1 January-31 December 2020). Demographic data, tumour characteristics, type of treatment and diagnosis times were comparable. PSA levels were recorded at consultation prior to biopsy and after treatment. Mann-Whitney and chi-square tests were used to compare continuous variables and percentages, respectively.Results: In 2020, there were fewer urology consultations (35,160 vs. 40,225 in 2019). The median PSA in 2020 was significantly higher (14.3 vs. 9.9 ng/dL in 2019). In 2019, 53.1% (N=264) of the biopsies were positive for cancer versus 47.2% (N=137) in 2020 (P=0.104). In 2020, more patients presented with metastatic disease (7.3% vs. 1.9%, P=0.009). Also, in 2020 there was a longer waiting time for prostate biopsy (42.2 vs. days in 2019, P=0.019). A total of 132 patients underwent laparoscopic radical prostatectomy (LARP).The mean time until surgery was similar in both years (71 vs. 58 days). During 2020, a higher percentage of patients had ISUP grade 4 in the surgical specimen (34.3% vs. 17.5%, P=0.07). Furthermore, a higher percentage of aggressive (pT3) tumours were diagnosed (37.2% vs. 27.2%, P=0.08), and the percentage of patients with involvement of surgical margins was also higher (48.6% vs. 29.3%, P=0.027). There were no differences between the groups in terms of biochemical recurrence or persistent PSA at one year (P=0.711).Conclusions: Delayed biopsy during the COVID-19 period did not appear to adversely impact biopsy results. Patients biopsied in 2020 had higher PSA, possibly due to proper triaging. A higher rate of adverse pathology outcomes was observed in patients undergoing radical prostatectomy during the pandemic, probably due to understaging of the biopsy. This study serves to raise awareness of the risk of deterioration of care of PC patients due to possible underdiagnosis.

show abstract

“…In England, the number of men diagnosed with PC, as well as the number of curative intent procedures performed, decreased significantly after the start of the first lockdown in 2020, and men diagnosed in 2020 were typically at a more advanced stage (12). by Contrast, in the Netherlands, while the number of new diagnoses did decrease in the first COVID-19 wave, as compared to the 2018-2019 period, the stage at diagnosis remained stable (13). However, it is debatable whether any impact of the lockdown would be expected to be evident so early.…”

Section: Editorialmentioning

confidence: 95%

The impact of coronavirus disease 2019 (COVID-19) pandemic on urologic cancer care: did we throw the baby out with the bathwater?

Kamecki¹,

Rajwa²,

Przewor³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands

Cited by 14 publications

References 18 publications

Lymphadenopathies before and during the Pandemic COVID-19: Increasing Incidence of Metastases from Solid Tumors

Lymphadenopathies before and during the Pandemic COVID-19: Increasing Incidence of Metastases from Solid Tumors

How has the COVID-19 pandemic influenced prostate cancer?—a tertiary single-centre analysis of oncological results, diagnosis and treatment times

The impact of coronavirus disease 2019 (COVID-19) pandemic on urologic cancer care: did we throw the baby out with the bathwater?

Contact Info

Product

Resources

About